A major new set of UK guidelines has just been published on how doctors and laboratories should diagnose serious fungal diseases. These come from the British Society for Medical Mycology (BSMM) and aim to make diagnosis faster, more accurate, and more consistent across the country.
For patients and families, this is very good news.
Why does this matter?
Fungal diseases can be difficult to diagnose. Many symptoms overlap with other conditions, and traditional tests sometimes miss infections. This can lead to delays, uncertainty, or unnecessary treatments.
The new BSMM recommendations help make sure that:
-
The right tests are used at the right time
-
Results come back more quickly
-
Hospitals know which modern tests give the best answers
-
Doctors can decide sooner whether antifungal treatment is needed
-
Unnecessary or ineffective treatments can be avoided
Overall, this means quicker diagnoses, fewer missed cases, and better care.
What is new in these guidelines?
The guidance highlights several improvements that directly benefit patients:
1. More accurate tests
Doctors are encouraged to use modern tests such as PCR, antigen tests, and antibody tests—these can detect fungal infections earlier and more reliably than traditional culture alone.
2. Faster turnaround times
Hospitals are encouraged to report important results within hours, not days. Faster answers mean faster treatment.
3. Better testing for people with chronic lung conditions
People with asthma, bronchiectasis, COPD, cystic fibrosis, or other long-term lung problems are now recognised as groups who may need access to fungal testing sooner.
4. Clearer pathways for difficult-to-diagnose conditions
Conditions such as chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), fungal bronchitis and invasive fungal infections now have clearer testing strategies.
5. Stronger links to antifungal stewardship
This means using antifungal medicines only when they are truly needed, helping prevent side-effects and resistance.
6. Guidance for hospitals with fewer resources
The document includes a step-by-step approach to help smaller or overseas hospitals improve gradually.
What does this mean for patients?
If you are living with, or being assessed for, a fungal condition, you should expect:
-
More consistent tests wherever you are treated in the UK
-
Better access to specialist testing when needed
-
Earlier and more confident diagnoses
-
More appropriate treatments, with less trial-and-error
-
Closer monitoring during treatment
These improvements could reduce anxiety, cut down on repeated appointments, and help your clinical team make clearer decisions.
Who should be following these guidelines?
-
Hospital laboratories
-
Doctors and nurses in respiratory, ICU, oncology, infectious diseases, and transplant services
-
GP practices referring patients for investigation
-
Healthcare commissioners
-
Hospitals outside the UK wanting to improve fungal care
Patients and carers can also play a part by asking:
“Does my hospital follow the latest BSMM recommendations for fungal testing?”
The bottom line
These new BSMM guidelines are a major step forward for anyone affected by fungal disease. They promote earlier diagnosis, better access to testing, safer treatment, and improved outcomes.
Putting these recommendations into everyday practice—across the UK and worldwide—has the potential to transform care and save lives.
Latest News posts
News archive